HomeNewsBusinessMarketsFor Nifty, 15,000 is a crucial level, expect the index to be in a range for now: Ashish Chaturmohta of Sanctum Wealth

For Nifty, 15,000 is a crucial level, expect the index to be in a range for now: Ashish Chaturmohta of Sanctum Wealth

It is important to note that COVID recoveries need to be more than the new daily cases and the recent recoveries are on the rise, resulting in a positive sign, said Chaturmohta.

May 09, 2021 / 07:47 IST
Story continues below Advertisement

Till the time Nifty stays below 15,000, we expect the consolidation to continue. It could hover in the range of 14,400-15,000. Meanwhile, while the action continues to be in the broader market - mid and smallcap stocks, Ashish Chaturmohta, Head of Derivatives and Technical Analysis, Sanctum Wealth Management said in an interview with Moneycontrol’s Kshitij Anand.

Edited excerpts:

Story continues below Advertisement

Q) A volatile week but bulls remained in control of D-Street pushing Nifty50 above 14,800 levels. What led to the price action? 

A) ‘Markets always discount the future. We had a massive fall in March 2020, but till that point, India didn't witness any large wave of COVID-19 cases nor had the lockdown begun, but markets discounted all of that before it began.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show